Rapport Therapeutics, Inc. (RAPP) Q3 FY2026 earnings

Reported results

• Net loss was $40.2 million for the third quarter of 2026, compared to $26.9 million for the prior year period.
• Net loss per share attributable to common stockholders, basic and diluted, was $0.84 for the three months ended September 30, 2026, compared to $0.71 for the three months ended September 30, 2025.
• Research and development expense was $34.3 million for the third quarter of 2026, compared to $22.3 million for the prior year period.
• Selling, general and administrative expense was $9.8 million for the third quarter of 2026, compared to $7.7 million for the prior year period.
• Cash, cash equivalents and short-term investments, excluding restricted cash, totaled $395.0 million as of September 30, 2026, compared to $436.1 million as of June 30, 2026.

Guidance

• Rapport Therapeutics expects that cash, cash equivalents, and short-term investments as of September 30, 2026, together with net proceeds from October and November 2026 financings and sales through its ATM program, will enable it to fund operating expenses and capital expenditure requirements through the end of 2029.

Price and volatility reaction

The stock moved +1.9% on the print. No front-expiry chain was on file, so there is no straddle expected move.

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-04 (8-K, Item 2.02). Read the original filing on sec.gov.